Kura Oncology (KURA)
NASDAQ:KURA
Want to see KURA full AI Analyst Report?
KURA Stock Chart & Stats
$9.68
-$0.35(-4.35%)
At close: 4:00 PM EST
$9.68
-$0.35(-4.35%)
Day’s Range― - ―
52-Week Range$5.45 - $12.49
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.72M
Market Cap
$778.55M
Enterprise Value$890.69M
Total Cash (Recent Filing)$580.82M
Total Debt (Recent Filing)$24.27M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Jul 30, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding88,774,370
10 Day Avg. Volume2,692,976
30 Day Avg. Volume1,723,670
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue12.43
Enterprise Value/Gross Profit13.14
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$28.11Price Target Upside190.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.55
Revenue Forecast (FY)$94.73M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumSustained early real‑world uptake, repeat prescriptions and physician switching indicate product–market fit and durable commercial traction. High initial script volume across ~60 activated accounts and rapid script‑to‑patient turnaround support scalable revenue growth as the company expands access and sales coverage.
Multi‑year Collaboration Funding And GuidanceVisible multi‑year funding from collaboration payments and explicit guidance reduces near‑term financing risk and allows focused investment in Phase 3 execution. This funding runway supports critical readouts and commercialization activities, increasing the probability management can advance programs without urgent dilutive financings.
Darlifarnib Platform Validated By ASCO DataRepeat clinical validation across indications signals a durable platform opportunity beyond a single asset. Strong combo activity and planned platform study can diversify pipeline, create multiple development paths, and establish differentiated clinical positioning versus competitors in KRAS and other targeted therapy landscapes.
Bears Say
Negative Operating Cash Flow And BurnThe company has swung from positive free cash flow in 2024 to sizable cash burn in 2025 and TTM, implying ongoing financing needs. Persistent negative operating cash flow elevates execution and funding risk over the next 2–4 years absent sustained commercial revenue or material collaboration receipts.
Deep Unprofitability And Widening LossesRising R&D and SG&A have widened net losses, keeping returns on equity sharply negative and eroding equity base. Without persistent commercial scale or successful late‑stage readouts, continued operating losses will pressure capital needs and make achieving self‑sustaining profitability more challenging.
Equity Incentive Expansion Raises Dilution RiskLarge increases to option and ESPP share pools heighten potential future dilution at a time of ongoing losses and financing needs. While aiding retention and execution, added share supply can dilute future per‑share economics and constrain upside for existing holders if growth and profitability do not outpace issuance.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.45 and its highest was $12.49 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $778.55M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Jul 30, 2026 which is in 54 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on May 12, 2026. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$0.835 by $0.005.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.9.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,774,370 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.83 in its last earnings report, beating expectations of -$0.835. Following the earnings report the stock price went up 1.788%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.11 (190.40% Upside)
$28.11 (190.40% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 203.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.96%
12-Months-Change
Fundamentals
Return on Equity
-141.95%
Trailing 12-Months
Asset Growth
-12.26%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
KURA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive commercial and clinical outlook: Comzifty's first full quarter produced $5.8M in revenue with strong early adoption signals (85 new patient starts, repeat prescriptions, switching, broad payer coverage >93%, rapid access times). The pipeline is active with multiple near‑term clinical catalysts (EHA, ASCO, multiple combination readouts) and COMMODORE‑17 enrollment is ahead of plan. Offsetting these positives are rising R&D and SG&A spending that widened the net loss (~27.7%), a quarter‑over‑quarter dip in collaboration revenue (~11.4%), and a roughly 13% decrease in cash vs. year‑end 2025. Management expects collaboration payments to extend runway and maintained multi‑year collaboration revenue guidance. Overall, the operational and clinical momentum appears to outweigh the near‑term financial headwinds, though continued execution and monitoring of burn and clinical readouts will be critical.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$28.11
▲(190.40% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Ownership Overview
2.46% Insiders
10.73% Mutual Funds
41.20% Other Institutional Investors
30.45% Public Companies and Individual Investors